Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
Titel:
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
Auteur:
Sydes, M.R. Spears, M.R. Mason, M.D. Clarke, N.W. Dearnaley, D.P. de Bono, J.S. Attard, G. Chowdhury, S. Cross, W. Gillessen, S. Malik, Z.I. Jones, R. Parker, C.C. Ritchie, A.W.S. Russell, J.M. Millman, R. Matheson, D. Amos, C. Gilson, C. Birtle, A. Brock, S. Capaldi, L. Chakraborti, P. Choudhury, A. Evans, L. Ford, D. Gale, J. Gibbs, S. Gilbert, D.C. Hughes, R. McLaren, D. Lester, J.F. Nikapota, A. O’Sullivan, J. Parikh, O. Peedell, C. Protheroe, A. Rudman, S.M. Shaffer, R. Sheehan, D. Simms, M. Srihari, N. Strebel, R. Sundar, S. Tolan, S. Tsang, D. Varughese, M. Wagstaff, J. Parmar, M.K.B. James, N.D.